Haematology Research Review, Issue 26

In this Issue:

Cytogenetic heterogeneity negatively impacts AML outcomes
ASXL1 mutations in younger adults with AML
Weekly bortezomib + dexamethasone in new MM
Bortezomib-based treatment of new MCL
R-MPV followed by high-dose chemotherapy and SCT for new primary CNS lymphoma
Brentuximab vedotin in relapsed/refractory DLBCL with variable CD30 expression
Mogamulizumab in previously treated cutaneous T-cell lymphoma
Follicular lymphoma in Sweden in the rituximab era
OS and competing risks of death in WM

Please login below to download this issue (PDF)